Other Clinical Trial - Treating Post-Lyme Disease Syndrome With

Clinical Trial Description

To access the effectiveness of Acetogenins in treating Post-Lyme Disease Syndrome (PLDS). After failure of antibiotic therapy to relive persistent symptoms of Lyme Disease, the use of Acetogenins to elevate Post-Lyme Disease Syndrome. ;

Study Design

Related Conditions & MeSH terms

Lyme Disease
Post-Lyme Disease Syndrome (PLDS)
Syndrome

See also
	Status	Clinical Trial	Phase
	Completed	`NCT04141969` - A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome	Phase 2/Phase 3

See also

Status

Clinical Trial

Phase

Completed

NCT04141969 - A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome

Phase 2/Phase 3

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04078841
Study type	Interventional
Source	Optimal Health Research
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	July 1, 2019
Completion date	January 30, 2020

Treating Post-Lyme Disease Syndrome With Acetogenins

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms